It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glass vials are the most widely used primary containers for the packaging of parenteral products due to their optical clarity, general inertness, and hermetic properties, but under certain circumstances, they can pose safety concerns. Most of these issues are related to the potential formation of glass particulates through delamination or precipitation, resulting from the chemical interaction between the drug product and the inner surface of the glass vial. Hence, it is imperative for pharmaceutical companies to conduct product-vial compatibility studies to determine the appropriate packaging/container closure system. To support this development activity, scientists need to develop analytical methods to detect subvisible glass particulates in parenteral products, along with the appropriate positive controls, to facilitate detection and identification. This paper outlines the utilization of coaxial/episcopic and oblique illumination microscopy, combined with spectroscopic techniques, to detect thin glass particulates generated from a modified procedure. It also showcases the importance of angle-dependent lighting in visualizing positive control samples containing thin glass particulates. The analytical microscopy techniques discussed in this paper can assist scientists in selecting suitable container closure systems for developing parenteral products.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Gilead Sciences Inc, Analytical Development and Operations, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
2 Gilead Sciences Inc, Analytical Development and Operations, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634); ORIC Pharmaceuticals Inc., South San Francisco, USA (GRID:grid.418227.a)
3 Gilead Sciences Inc, Development and Technical Services, La Verne, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
4 Gilead Sciences Inc, Process Technologies and Development, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)
5 Gilead Sciences Inc, Pharmaceutical Development and Technology, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634)